MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 9.5% – Here’s Why

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA)’s share price dropped 9.5% during trading on Thursday . The company traded as low as $1.33 and last traded at $1.33. Approximately 1,003,093 shares traded hands during mid-day trading, an increase of 64% from the average daily volume of 610,815 shares. The stock had previously closed at $1.47.

MAIA Biotechnology Price Performance

The firm has a market cap of $79.04 million, a price-to-earnings ratio of -1.94 and a beta of 0.22. The firm has a fifty day simple moving average of $1.36 and a two-hundred day simple moving average of $1.57.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. Equities analysts anticipate that MAIA Biotechnology, Inc. will post -0.52 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Stan Smith purchased 75,000 shares of the company’s stock in a transaction on Monday, June 1st. The shares were acquired at an average price of $1.34 per share, for a total transaction of $100,500.00. Following the purchase, the director owned 1,519,178 shares in the company, valued at $2,035,698.52. This trade represents a 5.19% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vlad Vitoc purchased 72,700 shares of the company’s stock in a transaction on Monday, June 1st. The shares were purchased at an average price of $1.39 per share, for a total transaction of $101,053.00. Following the purchase, the chief executive officer owned 976,121 shares in the company, valued at approximately $1,356,808.19. The trade was a 8.05% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 149,700 shares of company stock valued at $204,233 in the last 90 days. 19.81% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On MAIA Biotechnology

Institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after buying an additional 7,746 shares during the period. Marshall Wace LLP acquired a new stake in MAIA Biotechnology during the 2nd quarter valued at approximately $29,000. Jane Street Group LLC acquired a new stake in MAIA Biotechnology during the 2nd quarter valued at approximately $52,000. Ritholtz Wealth Management purchased a new stake in shares of MAIA Biotechnology in the 4th quarter valued at $35,000. Finally, Centric Wealth Management boosted its holdings in shares of MAIA Biotechnology by 2.0% in the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock valued at $897,000 after acquiring an additional 11,500 shares during the last quarter. Institutional investors and hedge funds own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.